Surgery Partners (SGRY) Cash & Equivalents (2014 - 2026)

Surgery Partners (SGRY) has 13 years of Cash & Equivalents data on file, last reported at $182.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 20.5% year-over-year to $182.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $182.3 million (down 20.5% YoY) and the FY2025 annual result came in at $239.9 million, down 10.98% from the prior year.
• Cash & Equivalents declined to $182.3 million in Q1 2026 per SGRY's latest filing, from $239.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $378.9 million in Q1 2022, with the low at $154.8 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $229.0 million, with a median of $227.4 million recorded in 2022.
• Year-over-year, Cash & Equivalents plunged 53.15% in 2022 and jumped 52.45% in 2023.
• Surgery Partners' Cash & Equivalents stood at $282.9 million in 2022, then tumbled by 30.75% to $195.9 million in 2023, then jumped by 37.57% to $269.5 million in 2024, then retreated by 10.98% to $239.9 million in 2025, then fell by 24.01% to $182.3 million in 2026.
• Business Quant data shows SGRY's Cash & Equivalents at $182.3 million in Q1 2026, $239.9 million in Q4 2025, and $203.4 million in Q3 2025.